- Price band
- To be announcedNot in this filing
- Issue size
- To be announcedAmount set with price
- Face value
- ₹1per equity share
- Lot size
- To be announcedMin. investment shown once set
- OpensMon, 2026
- ClosesWed, 2026
- AllotmentThu, 2026
- ListingMon, 2026
Dates marked in the offer document as tentative. Times in IST.
Information only, not investment advice. This page provides information compiled from official offer documents for information purposes only. It is not investment advice or a recommendation to apply for, buy or sell any security. We are not a SEBI-registered investment adviser or research analyst. Investments in IPOs are subject to market risks; read the offer document carefully before investing.
Issue details
- Issue type
- Book built, fresh issue and offer for sale
- Fresh issue
- —
- Offer for sale
- 91,66,000 shares
- Total issue
- —
- Face value
- ₹1
- Listing at
- NSE, BSE
- RHP date
- 3 Aug 2026
Source: Red Herring Prospectus dated 3 Aug 2026Updated
Subscription
Category-wise subscription is published by the exchanges while the issue is open. It appears here once the figures are added.
Valuation
FY 2025-26- EPS (basic)
- ₹14.77
- EPS (diluted)
- ₹14.77
- RoNW
- 14.55%
- NAV per share
- ₹101.51
- ROCE
- 17.55%
- EBITDA margin
- 22.56%
- PAT margin
- 11.28%
P/E and market cap are calculated once the price band is announced.
Source: Red Herring Prospectus dated 3 Aug 2026Updated
Financials
Consolidated, restated · ₹ crore| Period ended | 31 Mar 2026FY 2025-26 | 31 Mar 2025FY 2024-25 | 31 Mar 2024FY 2023-24 |
|---|---|---|---|
| Revenue from operations | 1,445.69 | 1,020.42 | 836.56 |
| Total income | 1,455.17 | 1,027.94 | 840.66 |
| EBITDA | 328.24 | 256.64 | 185.09 |
| Profit after tax | 164.14 | 138.58 | 83.54 |
| Net worth | 1,308.78 | 967.29 | 828.84 |
| Total assets | 2,148.42 | 1,461.56 | 1,221.06 |
| Total borrowing | 412.64 | 123.16 | 174.58 |
FY 2025-26 vs FY 2024-25: revenue +41.7%, profit after tax +18.4%.
Source: Red Herring Prospectus dated 3 Aug 2026Updated
About the company
The company develops and sells point-of-care molecular diagnostic devices and test kits, mainly under its Truenat platform. It also offers radiology, digital pathology and related devices through subsidiaries and partners, and sells to government programmes, aid agencies and private customers in India and abroad.
- Incorporated
- 2000
- Industry
- Medical Diagnostics
- CIN
- U33125GA2000PLC002909
- Website
- molbiodiagnostics.com
Source: Red Herring Prospectus dated 3 Aug 2026Updated
Promoters and shareholders
| Name | Before issue | After issue | Shares offered |
|---|---|---|---|
| Exxora Trading LLP | — | — | 18,11,000 |
| Dr. Chandrasekhar Bhaskaran Nair | — | — | 12,21,000 |
| India Business Excellence Fund III | — | — | 10,00,000 |
| Gopalkrishna Mangalore Kini | — | — | 11,25,000 |
| J. Guru Dutt | — | — | 9,02,000 |
| Gopalakrishna Sampathgiri | — | — | 9,02,000 |
| Sangeetha M Kini | — | — | 4,52,000 |
| M.A. Usha Rani | — | — | 4,51,000 |
| M.A. Rohit | — | — | 2,48,000 |
| Shruthi G Kini | — | — | 2,26,000 |
| Chewbacca Services Limited | — | — | 1,93,000 |
| Sujay Limited | — | — | 1,93,000 |
| Abdul Qadir Mohamed Theruvath | — | — | 48,000 |
| M.A. Sharath | — | — | 2,02,000 |
| M Ganesh Kamath | — | — | 17,000 |
| Shaheeda Abdul Kader | — | — | 97,000 |
| Vivek Devaraj | — | — | 78,000 |
Source: Red Herring Prospectus dated 3 Aug 2026Updated
Objects of the issue
₹ crore| Purpose | Amount |
|---|---|
| Capital expenditure for R&D facility and Centre of Excellence infrastructure (operated via subsidiary Bigtec) | 105.54 |
| Capital expenditure for plant, machinery and equipment at Goa Units I and II and Visakhapatnam Unit | 72.28 |
| General corporate purposes (not exceeding 25% of gross proceeds) | Set with price |
Source: Red Herring Prospectus dated 3 Aug 2026Updated
Peer comparison
As listed in the offer document| Company | EPS | P/E | RoNW | NAV per share |
|---|---|---|---|---|
| Molbio Diagnostics LimitedIssuer | ₹14.77 | — | 14.55% | ₹101.51 |
| Poly Medicure Limited | ₹31.79 | 52.61× | 10.37% | ₹306.45 |
| Dr. Lal Pathlabs Limited | ₹30.24 | 62.20× | 20.78% | ₹145 |
| Metropolis Healthcare Limited | ₹9.19 | 63.72× | 12.56% | ₹72.98 |
| Vijaya Diagnostics Centre Limited | ₹16.81 | 81.02× | 18.07% | ₹93.02 |
Source: Red Herring Prospectus dated 3 Aug 2026Updated
Strengths and risks
Our summary of what the offer document statesStrengths
- Proprietary portable point-of-care molecular platform (Truenat) with ICMR and WHO-endorsed TB testing.
- Recurring test-kit revenue tied to the installed device base.
- Tests offered for 30 diseases through 43 assays.
- In-house R&D through a wholly-owned subsidiary, with a sizeable patent portfolio.
- Certified quality management system (ISO 13485 and MDSAP).
Risks
- Large share of revenue depends on government and international aid agency programmes.
- Top 10 customers account for over 80% of product revenue in each of the last three years.
- About 70% of revenue comes from tuberculosis test kits.
- Objects of the Fresh Issue have not been appraised by any external agency.
- Part of the Bigtec R&D IP is used under an intellectual property agreement with a related subsidiary.
Source: Red Herring Prospectus dated 3 Aug 2026Updated
Contacts
Source: Red Herring Prospectus dated 3 Aug 2026Updated
Allotment status
Check whether shares were allotted on the official pages below, using your PAN, application number or DP/client ID. Results appear once the basis of allotment is finalised.
- Allotment
- Refunds
- Demat credit
- Listing
Source: Red Herring Prospectus dated 3 Aug 2026Updated
After listing
Listing price, day-one high and low, and the change from the issue price (set at allotment) appear here after the shares list on NSE and BSE.
Frequently asked questions
When does the Molbio Diagnostics IPO open and close?
According to the Red Herring Prospectus, the issue opens on Monday, 10 August 2026 and closes on Wednesday, 12 August 2026.
What is the Molbio Diagnostics IPO price band?
The Red Herring Prospectus does not include a price band. The company announces it by advertisement before the issue opens, and this page is updated when it is filed.
Where will Molbio Diagnostics shares list?
On NSE and BSE. The tentative listing date is Monday, 17 August 2026.
Who is the registrar of the issue?
KFin Technologies Limited (SEBI registration INR000000221). Allotment status is checked on the registrar's website.
How do I check the Molbio Diagnostics IPO allotment status?
The basis of allotment is expected to be finalised on Thursday, 13 August 2026. After that, search by PAN, application number or DP/client ID on the registrar's website (KFin Technologies Limited), the NSE website or the BSE website. Shares that are allotted are credited to your demat account; for an application that is not allotted, the blocked amount is released.
How will the money raised be used?
₹105.54 Cr for capital expenditure for R&D facility and Centre of Excellence infrastructure (operated via subsidiary Bigtec), ₹72.28 Cr for capital expenditure for plant, machinery and equipment at Goa Units I and II and Visakhapatnam Unit, and the rest for the other stated purposes.
Related IPOs
Also managed by Kotak Mahindra Capital Company
- Jio Platforms₹1,119Listed · 21 Oct – 23 Oct 2026
- Zetwerk Manufacturing Businesses₹151Listed · 15 Oct – 19 Oct 2026
- Moneyview₹34Listed · 24 Sept – 28 Sept 2026
- National Stock Exchange of India₹1,785Listed · 17 Sept – 21 Sept 2026
Spotted something wrong?
Our data comes from official offer documents, but mistakes can slip through. Report an error and tell us which figure looks wrong and where you saw the correct one (the offer-document page number helps). For anything else, see Contact.